<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01957878</url>
  </required_header>
  <id_info>
    <org_study_id>PC10VAC02</org_study_id>
    <nct_id>NCT01957878</nct_id>
  </id_info>
  <brief_title>Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL</brief_title>
  <acronym>RHEIA-VAC</acronym>
  <official_title>A Double-blind, Randomised, Placebo-controlled, Phase II Study to Evaluate ProCervix Efficacy to Clear HPV 16 and HPV 18 Infection in Women With Normal Cytology or ASCUS/LSIL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genticel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genticel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human Papillomavirus (HPV) 16 and HPV 18 (the two virus genotypes targeted by the ProCervix&#xD;
      vaccine) are the most common HPV genotypes associated with at least 70% of squamous cell&#xD;
      carcinomas and 82% of adenocarcinomas of the cervix The strategy of therapeutic vaccination&#xD;
      with ProCervix is to activate and enhance the patient's cellular immune response to HPV . The&#xD;
      therapeutic vaccine will be used for women infected by HPV 16, HPV 18, or both. The vaccine&#xD;
      targets these HPV infected women with normal or mild cervical cellular dyskaryosis as&#xD;
      detectable infections with oncogenic potential.&#xD;
&#xD;
      This will be a double-blind, randomised, placebo-controlled, parallel group study assessing&#xD;
      the efficacy of ProCervix or placebo (concomitantly administered with imiquimod cream).&#xD;
&#xD;
      ProCervix will be delivered with a topical agent, imiquimod, applied to the injection sites&#xD;
      as a vaccine adjuvant.&#xD;
&#xD;
      The population proposed for this study represents an otherwise healthy female population who&#xD;
      are infected with HPV 16 and/or HPV 18. The safety and tolerability of this therapeutic&#xD;
      vaccine has been shown in the ongoing Phase I study, and the proposed population may in&#xD;
      theory derive benefit from this vaccine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance of HPV 16 and HPV 18 infection at Month 12 using a type specific, sensitive and quantitative HPV PCR assay.</measure>
    <time_frame>month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clearance of HPV 16 and HPV 18 infection.</measure>
    <time_frame>Month 6, 15, 18, 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">239</enrollment>
  <condition>Genital Infection Viral</condition>
  <condition>HUMAN PAPILLOMA VIRUS</condition>
  <arm_group>
    <arm_group_label>HPV therapeutic vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo matching ProCervix</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ProCervix</intervention_name>
    <description>ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod</description>
    <arm_group_label>HPV therapeutic vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod</description>
    <arm_group_label>Placebo matching ProCervix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A subject will be eligible for inclusion in this study if the following criteria&#xD;
             apply:&#xD;
&#xD;
               1. Subject is female between the ages of 25 and 50 years (inclusive).&#xD;
&#xD;
               2. Subject is pre-menopausal .&#xD;
&#xD;
               3. Subject must have cervical HPV 16 and/or 18 infection confirmed by RT-PCR&#xD;
&#xD;
               4. Subject has a cervical cytological evaluation with a normal, ASCUS or LSIL result&#xD;
                  at baseline.&#xD;
&#xD;
               5. Subject has employed highly effective contraception the month prior to the first&#xD;
                  vaccination and will agree to employ highly effective contraception for at least&#xD;
                  12 months after the first vaccination. .&#xD;
&#xD;
               6. Subject is in general good health based on medical history and physical&#xD;
                  examination.&#xD;
&#xD;
               7. Subject is able to communicate effectively with study personnel and is considered&#xD;
                  reliable, willing, and cooperative in terms of compliance with the protocol&#xD;
                  requirements.&#xD;
&#xD;
               8. Subject voluntarily gives written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has a current acute or chronic disease, other than infection with HPV, which&#xD;
             would be expected to interfere with the planned evaluations of response&#xD;
&#xD;
          2. Subject has vaginal atrophy with or without topical hormonal therapies or systemic&#xD;
             selective estrogen receptor modulators (SERMs).&#xD;
&#xD;
          3. Subject has prior exposure to HPV prophylactic vaccine or subject has participated in&#xD;
             the past in another vaccination clinical trial related to infection with HPV&#xD;
&#xD;
          4. Current high grade lesions or history of untreated high grade cervical lesion (either&#xD;
             CIN2 or CIN3).&#xD;
&#xD;
          5. Subject has current or a history of cancer of the cervix.&#xD;
&#xD;
          6. Subject has clinically significant (CS) gynaecological abnormalities that could&#xD;
             interfere with study evaluation, in the judgment of the Investigator (e.g. prolapse,&#xD;
             myoma, fibroid, hysterectomy).&#xD;
&#xD;
          7. Subject has a laboratory abnormality Grade ≥ 2, as defined using the Toxicity Grading&#xD;
             Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine&#xD;
             Clinical Trials,&#xD;
&#xD;
          8. Subject has received any live viral vaccine within 3 months or any other non live&#xD;
             vaccine within 2 weeks of first study product administration.&#xD;
&#xD;
          9. Subject has primary or secondary systemic immunosuppression&#xD;
&#xD;
         10. Subject has a history of severe allergy (requiring hospital care) or history of severe&#xD;
             asthma&#xD;
&#xD;
         11. Subject has a history of malignant cancer, except the following adequately treated&#xD;
             cancers: basal cell carcinoma, or dermatological squamous cell carcinoma.&#xD;
&#xD;
         12. Subject was administered with another investigational drug or vaccine within 30 days&#xD;
             prior to the screening visit or is participating in any other study.&#xD;
&#xD;
         13. Subject has a known hypersensitivity to imiquimod.&#xD;
&#xD;
         14. Subject has a history of severe reaction to any drug or vaccination.&#xD;
&#xD;
         15. Subject has a medical condition with clinical and/or biological consequences judged by&#xD;
             the Investigator incompatible with vaccination(s).&#xD;
&#xD;
         16. Subject has positive results for human immunodeficiency virus (HIV), hepatitis B virus&#xD;
             (HBV) surface antigen (HBsAg), or hepatitis C virus (HCV).&#xD;
&#xD;
         17. Subject has a symptomatic vaginal or genital infection&#xD;
&#xD;
         18. Subject has a history of or currently active genital herpes disease.&#xD;
&#xD;
         19. Subject is pregnant or is breastfeeding.&#xD;
&#xD;
         20. Subject has a positive serum human chorionic gonadotrophin (HCG) result at enrolment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Regionaal Ziekenhuis Heilig Hart Tienen Hospital</name>
      <address>
        <city>Tienen</city>
        <state>Vlaams Brabant</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for the Evaluation of Vaccination Vaccine &amp; Infectious Disease Institute (VAXINFECTIO) Faculty of Medicine University of Antwerp Belgium</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi Site Notre-Dame</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopistollinen sairaala Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Hopital Sud</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Jacques</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GORH, CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandre CHU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes - Hopital Universitaire Caremeau</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique de Vaccinologie Cochin Pasteur (CIC BT505)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims Institut Alix de Champagne</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin Hospital</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen Hospital</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth Krankenhaus Essen GmbH - Clinic/Outpatient Facility</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Friedrich Schiller Universität Jena Hospital</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universität- Hospital</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wolfsburg Hospital</name>
      <address>
        <city>Wolfsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center Gynaecological Oncology Amsterdam AMC, NKI-AVL, VUmc</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Dept of Obstetrics and Gynecology C/ Villarroel Unidad de Ginecología Oncológica, Instituto Clínico de Ginecología y Obstetricia y Neonatología (ICGON), Hospital Clínic, Instituto de Investigaciones Biomédi</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia L'Hopitalet de Llobregat</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ginecologica Ceoga, Clinic/Outpatient Facility</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz de Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario &quot;12 de Octubre&quot;</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya - Hospital Materno Infantil</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sagrado Corazón de Sevilla</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dumfries and Galloway Royal Infirmary Hospital</name>
      <address>
        <city>Dumfries</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool - GUM - Liverpool Centre for Sexual Health</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mary's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic O&amp;G University of Manchester Research - St Mary's Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Centre for Immunology and Infection Hull York Medical School University of York</name>
      <address>
        <city>York</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>October 4, 2013</study_first_submitted>
  <study_first_submitted_qc>October 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>December 1, 2016</last_update_submitted>
  <last_update_submitted_qc>December 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Papilloma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

